Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Sitagliptin in Type I Diabetic Patients
NCT01741103 · University at Buffalo · NA · withdrawn · last registry update 2022-03-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study funding was for 1 year to a fellow who graduated in early stages of enrollment. While 6 patients were enrolled, many patients didn't finish the study and therefore little data was collected and no results will be entered.” | – | Registry record, University at Buffalo |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DPP4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-03-23Phase 3 first posted: Shenzhen Salubris Pharmaceuticals Co., Ltd., SAL067 + Alogliptin (NCT05782192)
- 2023-02-21Results posted on the registry: University at Buffalo, Linagliptin + Placebo (NCT02372630)
- 2023-02-16Also stopped (terminated): Erasme University Hospital, Incretinomimetics + DPP-4 inhibitors (NCT02244164)
- 2023-01-19Results posted on the registry: George Washington University, Linagliptin + Placebo (NCT02467478)
- 2022-12-07Phase 3 first posted: Huashan Hospital, Insulin Degludec and Insulin Aspart (NCT05641337)
- 2022-11-15Also stopped (withdrawn): Icahn School of Medicine at Mount Sinai, Exendin 9-39 and Sitagliptin + Placebo (NCT02697253)
- 2022-10-19Results posted on the registry: Takeda, Alogliptin Benzoate + Placebo (NCT02856113)
- 2022-08-17Phase 3 first posted: Handok Inc., Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet + Teneligliptin Placebo Oral Tablet (NCT05504226)
- 2022-08-17Phase 3 first posted: Handok Inc., Teneligliptin (as Teneligliptin Hydrobromide) 20 Mg Oral Tablet + Teneligliptin Placebo Oral Tablet (NCT05504239)
- 2022-08-16Results posted on the registry: Vanderbilt University Medical Center, Liraglutide + Sitagliptin (NCT03101930)
- 2022-07-27Also stopped (withdrawn): EMS, LIMA association + Tradjenta (NCT03766750)
- 2022-07-21Results posted on the registry: University at Buffalo, Januvia (Sitagliptin) 100 mg + Placebo (NCT00659711)
- 2022-05-31Also stopped (terminated): AstraZeneca, Dapagliflozin 10 mg + Dapagliflozin 5 mg (NCT03608358)
- 2022-05-11Phase 3 first posted: Tanta University, Alpha lipoic acid + Roflumilast (NCT05369793)
- 2022-03-22Phase 3 first posted: National University of Malaysia, Dipeptidyl-Peptidase IV Inhibitors (NCT05290506)
- 2022-03-14Results posted on the registry: Population Health Research Institute, insulin glargine + sitagliptin/metformin (NCT02623998)
- 2022-02-09Results posted on the registry: University of Pennsylvania, Sitagliptin + Placebo (NCT01879228)
- 2022-02-02Phase 3 first posted: University of Milan, Sitagliptin (NCT05219409)
- 2022-01-28Results posted on the registry: Tanabe Pharma Corporation, Teneligliptin 20mg + Placebo (NCT02916706)
- 2022-01-28Results posted on the registry: Tanabe Pharma Corporation, Teneligliptin 20mg + Placebo (NCT02924064)
- 2021-12-08Phase 3 first posted: The First Affiliated Hospital of Soochow University, Sitagliptin + Standard Prophylaxis + Standard Prophylaxis (NCT05149365)
- 2021-12-03Phase 3 first posted: REDNVIA Co., Ltd., Evogliptin + Placebo (NCT05143177)
- 2021-11-01Phase 3 first posted: PegBio Co., Ltd., PB-201 + Vildagliptin (NCT05102149)
- 2021-10-11Also stopped (withdrawn): Rush University Medical Center, metformin and sitagliptin + insulin glargine and insulin lispro (NCT02250794)
- 2021-07-26Results posted on the registry: Vanderbilt University, Placebo + Sitagliptin (NCT02130687)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision